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Glomerular ultrafiltration and apical tubular action of IGF-I, aspects of such growth factor ligand–receptor interac-
TGF-b, and HGF in the nephrotic syndrome. In nephrotic tions, as they may apply to glomerular proteinuria. Such
glomerulopathies, there is ultrafiltration of high molecular ligand-receptor pairs where the ligand is present in ultra-weight forms of insulin-like growth factor-I (IGF-I), hepatocyte
filtrate and the receptor is expressed in apical membranesgrowth factor (HGF), and transforming growth factor-b (TGF-b),
in tubular cells include insulin-like growth factor-Iwhich are bioactive in tubular fluid and act through apical
tubular receptors. Experimental evidence indicates that ul- (IGF-I)–IGF-I receptors, hepatocyte growth factor
trafiltered IGF-I, HGF, and TGF-b may contribute to in- (HGF)–p190met, transforming growth factor-b (TGF-b)–
creased tubular phosphate and sodium absorption, synthesis TGF-b type I/II receptors, and possibly HGF-like growthof extracellular matrix proteins, and secretion of chemokines
factor (HGFL–Ron).such as monocyte chemoattractant protein-1 (MCP-1). Through
these mechanisms, glomerular proteinuria may contribute to
tubulointerstitial pathobiology in nephrotic syndrome.
INTERACTION OF ULTRAFILTERED INSULIN-
LIKE GROWTH FACTOR-I WITH TUBULAR
CELL INSULIN-LIKE GROWTH FACTOR-IIn nephrotic glomerular diseases, there is a strong
RECEPTORS
association between the degree of proteinuria and the
Insulin-like growth factor-I (7.6 kDa) is present inonset and rate of progression of chronic renal failure.
serum at considerable levels (20 to 40 nm). However,Moreover, the onset and progression of renal failure are
more than 99% of serum IGF-I circulates in high molecu-tightly linked to tubulointerstitial injury such as tubular
lar weight protein complexes due to binding to specificatrophy, interstitial fibrosis, and a macrophage infiltrate
binding proteins [6]. Most (approximately 75%) of the[1–5]. This chain of events suggests that the glomerular
peptide is bound to IGF-binding protein (IGFBP)-3,ultrafiltration of proteins in nephrotic syndrome causes
which associates with an acid labile subunit (75 kDa)or contributes to tubulointerstitial pathobiology. Glo-
and the ligand to form a circulating complex of 150 kDa.merular protein ultrafiltration causes translocation of
Most of the remainder of serum IgI is present in com-bioactive molecules from plasma into tubular fluid.
plexes of approximately 50 kDa, where the peptide isThese include growth factors that are present in serum
bound to IGFBP-4, -2, or -1.in high molecular weight, largely inactive forms and are
Insulin-like growth factor-I receptors are expressed innot ultrafiltered in normal glomeruli. Moreover, func-
the nephron in basolateral but also in apical tubulartioning growth factor receptors are abundantly ex-
membranes. Apical IGF-I receptor expression has beenpressed in the kidney and are also distributed in apical
demonstrated in proximal tubules, thick ascending limbstubular membranes in some segments of the nephron.
of the loop of Henle, and cortical collecting ducts [7, 8].Glomerular ultrafiltration of these growth factors and
Although IGF-I is expressed in some nephron segments,their tubular action through respective apical receptors
it does not appear to be secreted into tubular fluid [9].may convey important mechanisms of tubulointerstitial
IGF-I is normally not expressed in proximal tubules [10].injury and may be an important avenue in the nephrotic
Hence, the natural ligand for apical (proximal) tubularsyndrome by which glomeruli and tubules become patho-
IGF-I receptors is most likely and exclusively IGF-I thatphysiologically linked.
originates from glomerular ultrafiltration.This and other laboratories have investigated different
Glomerular ultrafiltration of IGF-I/IGFBP-complexes
in the nephrotic syndromeKey words: apical tubular receptors, tubulointerstitial nephritis, pro-
teinuria, progressive renal disease. Insulin-like growth factor-I is either absent from nor-
mal glomerular ultrafiltrate or is present at extremely 1999 by the International Society of Nephrology
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Fig. 3. Western blot analysis of hepatocyte growth factor (HGF) in
serum, proximal tubular fluid (PTF), and urine under reducing condi-
tions in normal control animals (CO) and rats with diabetic nephropathy
Fig. 1. Western ligand blot of insulin-like growth factor (IGF)-binding (DM).
proteins in glomerular ultrafiltrate in rats with diabetic (DM) or adria-
mycin (ADR) nephropathy.
tor substrate (IRS)-1 (unpublished observation). More-
over, in proximal tubular cells that were incubated in
96-well plates, nephrotic rat glomerular ultrafiltrate in-
creases the uptake of 3H-thymidine into DNA, and this
activity of tubular fluid is, in part, blocked by coincuba-
tion with a neutralizing IGF-I receptor monoclonal anti-
body [11].
Other studies have provided direct or indirect experi-
mental evidence that ultrafiltered tubular fluid IGF-I
increases proximal tubular phosphate absorption and
distal tubular sodium absorption and tubular collagenFig. 2. Activation of IGF-I receptors in proximal tubular cells by glo-
merular ultrafiltrate. Suspended cells that were labeled with 32P were secretion (abstract; Wang and Hirschberg, J Am Soc
incubated with proximal tubular fluid from control (CO) or rats with
Nephrol, ibid) [8, 11, 12]. These studies exemplify thatadriamycin-induced nephrotic syndrome (ADR). Cells were lyzed, and
a growth factor, namely IGF-I, undergoes glomerularIGF-I receptors were immunoprecipitated. Precipitates were analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- ultrafiltration in nephrotic syndrome, activates specific
PAGE). The autoradiogram demonstrates increases in phosphorylation apical tubular receptors, initiates signal transduction, andof IGF-I receptor b-subunits upon incubation with nephrotic rat tubular
confers various pathophysiological consequences to tu-fluid.
bular cells.
HEPATOCYTE GROWTH FACTOR AND p190metlow levels, which do not allow for detection with avail-
Hepatocyte growth factor is synthesized and releasedable assays. However, in rat models of glomerular dis-
from tissues, mainly liver, as a biologically inactive, mo-eases such as the adriamycin-induced nephrotic syn-
nomeric precursor molecule. Pro-HGF (approximatelydrome or streptozotocin-induced diabetic nephropathy,
95 kDa) is cleaved by a specific serine protease (HGFIGF-I/IGFBP complexes are ultrafiltered into proximal
activator) in the extracellular environment into a ab-tubular fluid (Fig. 1). In studies from our laboratory,
dimeric, active molecule (approximately 82 kDa) con-IGF-I levels were measured by radioimmunoassay in
sisting of an a-chain (54 to 69 kDa, dependent on glyco-early proximal tubular fluid that was collected by neph-
sylation) and a 34 kDa b-chain.ron micropuncture from rats with adriamycin or diabetic
Hepatocyte growth factor is present in serum as bothnephropathy and were on average 1.35 and 2.54 nm,
the Pro- and mature molecule. In rats with diabetic ne-respectively (abstract; Wang and Hirschberg, J Am Soc
phropathy, HGF is ultrafiltered into proximal tubularNephrol, 9:124, 1998) [11].
fluid (abstract; Wang and Hirschberg, J Am Soc NephrolBioactivity of proximal tubular fluid IGF-I was exam-
8:632, 1997). Western blot analysis of diabetic rat proxi-ined in vitro in suspended mouse proximal tubular cells
mal tubular fluid demonstrates the presence of only ma-(mPTCs) after labeling of the cell ATP pool with 32P-
ture HGF (Fig. 3). Either Pro-HGF is ultrafiltered atorthophosphate. The incubation of labeled cells for two
low rates not allowing for visualization by Western blot,minutes with proximal tubular fluid that was obtained
or ultrafiltered Pro-HGF is quickly activated by proteol-from nephrotic rats by renal micropuncture activates
ysis. Indeed, urokinase, which is abundantly present inIGF-I receptors (Fig. 2) and initiates recruitment of
phosphatidylinositol-3-kinase to activated insulin recep- tubular fluid, has been shown to activate Pro-HGF [13].
Wang et al: IGF-I, TGF-b, and HGF in nephrotic syndrome 1249
The specific receptor for HGF is the protein product 1997). In this assay, mink lung epithelial cells that were
stably transfected with a TGF-b–sensitive truncated plas-of the met proto-oncogene p190met. The expression of
this heterodimeric tyrosine kinase receptor in the neph- minogen activator inhibitor-1 (PAI-1) promoter fused
to a luciferase reporter (kindly donated by Dan Rifkin,ron was recently examined in this laboratory in kidneys
from normal and streptozotocin diabetic rats by immu- New York University, New York, NY, USA) were
incubated in 96-well plates with medium containingnohistology (abstract; Wang and Hirschberg, J Am Soc
Nephrol 8:632, 1997). In diabetic rat kidneys, p190met is rhTGF-b1 (1 to 500 pg/ml) as standards or diluted nor-
mal or diabetic rat proximal tubular fluid (25 ml/well).expressed in apical membranes in S3 segments of proxi-
mal tubules, thick ascending limbs of the loop of Henle, After 16 hours, cells were washed and lyzed, and lucifer-
ase activity in lysates was measured by luminescencedistal tubules, and cortical and medullary collecting
ducts. assay.
In native or heat-activated (808C, 10 min) proximal
tubular fluid from normal rats, TGF-b levels were less
TRANSFORMING GROWTH FACTOR-b
than 10 pg/ml. In contrast, in rats with diabetic nephropa-
AND TRANSFORMING GROWTH
thy, the early proximal tubular fluid levels of active
FACTOR-b RECEPTORS
TGF-b were 76 6 43 pg/ml, and the total (bioactivatable)
Transforming growth factor-b (25 kDa) is a homodi- TGF-b levels were 729 6 272 pg/ml (N 5 5). These
meric growth factor peptide that is released from cells data not only indicate that TGF-b undergoes glomerular
as a precursor molecule bound to latency-associated pep- ultrafiltration, but they also demonstrate that at least a
tide (LAP) as a complex of 100 kDa, or bound to LAP- portion of TGF-b is bioactive in tubular fluid. It is possi-
LTBP (latent TGF-b binding protein, approximately 220 ble that further activation of ultrafiltered TGF-b occurs
kDa) or to a2-macroglobulin (approximately 900 kDa). such as with downstream acidification of tubular fluid
Most of the body content of TGF-b is present in platelets, [16].
but TGF-b1 is also present in plasma at considerable
levels (60 to 100 ng/ml), but in high molecular weight,
INDUCTION AND BASOLATERAL SECRETIONinactive forms.
OF MONOCYTE CHEMOATTRACTANTTransforming growth factor-b acts through two related
PROTEIN-1 BY ULTRAFILTERED HGFtransmembrane serine-threonine kinase receptor pro-
AND TGF-bteins, type I and II receptors [14]. Type II receptors bind
the ligand, resulting in recruitment of type I receptors Ultrafiltered HGF and TGF-b may induce several bio-
logical events to apical receptor-bearing tubular seg-into a heterodimeric I/II complex. In this ligand-acti-
vated complex, type II receptor kinase activates type I ments that cause or contribute to tubulointerstitial pa-
thobiology in proteinuric glomerulopathies. These mayreceptors by phosphorylation on ser-thr residues and
causes subsequent transmission of signals to intracellular include increased expression of extracellular matrix pro-
teins. TGF-b may contribute to tubular atrophy becausesubstrates such as Smads [14].
Transforming growth factor-b receptor expression in it can induce cell cycle arrest through activating cyclin
dependent kinase (CDK) inhibitors and induce proapo-the kidney has been examined by Ando et al [15], and
this laboratory has specifically studied the distribution ptotic signals [17].
Hepatocyte growth factor and TGF-b may also stimu-of type I and II receptors in apical and basolateral mem-
branes in the nephron in normal and diabetic rats (ab- late basolateral secretion of chemokines that subse-
quently act on the interstitium. One such molecule isstract; Wang and Hirschberg, J Am Soc Nephrol 8:648,
1997). In general, type I and II receptors are coexpressed monocyte chemoattractant protein-1 (MCP-1). MCP-1
has been associated with renal interstitial macrophagein the nephron in glomerular arterioles, cortical and med-
ullary collecting ducts, and papillary collecting ducts. In accumulation. Indeed, interstitial macrophages play a
role in the progression of proteinuric renal diseases [18].rats with streptozotocin-induced diabetic nephropathy,
there is also moderate TGF-b receptor expression in For example, in streptozotocin-induced diabetic ne-
phropathy at week 20 to 30, the number of ED-11 inter-some glomeruli (mesangium) and in apical membranes
of distal tubules and cortical and medullary collecting stitial macrophages is increased twofold compared with
control (abstract; Wang and Hirschberg, J Am Socducts.
The glomerular ultrafiltration of active and total Nephrol, 9:644, 1998). These cells secrete other growth
factors and cytokines, including TGF-b, that activateTGF-b has been examined in tubular fluid that was col-
lected by micropuncture from normal rats and from rats interstitial fibroblasts, resulting in increased extracellular
matrix protein deposition and interstitial fibrosis.with streptozotocin-induced diabetic nephropathy in this
laboratory using a highly sensitive and specific assay (ab- Recent studies from our laboratory suggest important
contributions of ultrafiltered HGF and TGF-b in MCP-1–stract; Wang and Hirschberg, J Am Soc Nephrol 8:648,
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mPTCs and mIMCD-3 cells that were grown to conflu-
ence on Anopore support membranes and were incu-
bated with rhTGF-b or rhHGF (1 nm) selectively in the
apical compartment, approximately two thirds of the
MCP-1 accumulated in the basolateral compartment.
In summary, these studies provide experimental evi-
dence that the glomerular ultrafiltration of high molecu-
lar weight growth factors in the nephrotic syndrome or
other glomerulopathies such as diabetic nephropathy
leads to an interaction with specific receptors in apical
tubular membranes. Specifically, ultrafiltered IGF-I may
induce increased tubular collagen production and may
raise proximal tubular phosphate and distal tubular NaFig. 4. Secretion of monocyte chemoattractant protein-1 (MCP-1) by
mouse proximal tubular cells (mPTCs) or mouse inner medullary col- absorption. Ultrafiltered HGF and TGF-b increase ex-
lecting duct cells (mIMCD-3) upon incubation with proximal tubular pression and basolateral secretion of MCP-1, which may
fluid (PTF) from rats with diabetic nephropathy.
contribute to the interstitial macrophage infiltrate in
these diseases. It is likely that there are other growth
factor-receptor pairs, such as HGFL–Ron, where the
ligand is present in glomerular ultrafiltrate and receptorsinduced recruitment of interstitial macrophages. The in-
are expressed in apical tubular membranes. Further-cubation of mPTCs or mouse inner medullary collecting
more, other tubular effects of these ultrafiltered growthduct cells (mIMCD-3) in 96-well plates with diluted prox-
factors may also contribute to tubulointerstitial pathobi-imal tubular fluid that was collected by micropuncture
ology in the nephrotic syndrome.from rats with diabetic nephropathy increases MCP-1
mRNA levels approximately twofold as measured by
Reprint requests to Raimund Hirschberg, M.D., Division of Nephrol-
quantitative reverse transcription-polymerase chain re- ogy, Harbor-UCLA Medical Center, Box 406, 1000 West Carson Street,
Torrance, California 90509, USA.action (P , 0.05; abstract; Wang and Hirschberg, J Am
E-mail: hirschberg@humc.eduSoc Nephrol, 9:644, 1998). Moreover, the incubation of
mPTC or mIMCD-3 with rhHGF or rhTGF-b (1 nm)
REFERENCESincreases MCP-1 mRNA threefold to fourfold compared
1. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R,with control (P , 0.05). In contrast, neither rhIGF-I nor
Gaspari F, Remuzzi G: Proteinuria predicts end-stage renal failureelevated glucose levels increase MCP-1 mRNA in these
in non-diabetic chronic nephropaties. Kidney Int 52(Suppl):S54–
cells. S57, 1997
2. Austin SM, Lieberman JS, Newton LD, Mejia M, Peters WA,The secretion of MCP-1 peptide into the medium upon
Myers BD: Slope of serial glomerular filtration rate and the pro-incubation of mPTCs and mIMCD-3 cells with diluted
gression of diabetic glomerular disease. J Am Soc Nephrol 3:1358–
proximal tubular fluid from diabetic rats was examined 1370, 1993
3. Eddy AA: Expression of genes that promote renal interstitialby enzyme-linked immunosorbent assay (ELISA) using
fibrosis in rats with proteinuria. Kidney Int 54(Suppl):S49–S54,a commercially available kit (R&D Systems, Minneapo-
1996
lis, MN, USA). This highly sensitive assay is specific for 4. Jackle I, Gunther W, von Gise H, Alt JM, Bohle A, Stolte H:
Kidney function and protein excretion in relation to pathomorphol-mouse MCP-1/JE and does not recognize rat MCP-1.
ogy of glomerular diseases. Contrib Nephrol 68:128–135, 1988Proximal tubular fluid from diabetic rats at a 1:5 dilution
5. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA,
induces a threefold to fourfold increase in MCP-1 that Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood
is secreted during 24 hours (Fig. 4). The HGF-induced pressure control, proteinuria, and the progression of renal disease:
The Modification of Diet in Renal Disease Study. Ann Intern Medstimulation of MCP-1 in mPTCs is partially blocked by
123:754–762, 1995
coincubation with Genistein or Wortmannin, suggesting 6. Hirschberg R, Kaysen GA: Insulin-like growth factor I and its
that this bioactivity of the growth factor is mediated binding proteins in the experimental nephrotic syndrome. Endocri-
nology 136:1565–1571, 1995through tyrosine kinase signaling pathways, more specifi-
7. Hammerman MR, Rogers S: Distribution of IGF receptors in the
cally, through pathways employing phosphatidylinositol-3 plasma membrane of proximal tubular cells. Am J Physiol
kinase. 253:F841–F847, 1987
8. Quigley R, Baum M: Effects of growth hormone and insulin-likeIt is conceivable that interstitial macrophages are at-
growth factor I on rabbit proximal convoluted tubule transport. J
tracted in vivo by MCP-1 that is specifically secreted Clin Invest 88:368–374, 1991
through basolateral tubular membranes. Hence, addi- 9. Hirschberg R: Insulin-like growth factor I in the kidney. Miner
Electrolyte Metab 22:128–132, 1996tional experiments were performed to demonstrate that
10. Matejka GL, Jennische E: IGF-I binding and IGF-I mRNA ex-
MCP-1 is secreted through basolateral membranes upon pression in the post-ischemic regenerating rat kidney. Kidney Int
42:1113–1123, 1992apical stimulation with HGF or TGF-b. Indeed, in
Wang et al: IGF-I, TGF-b, and HGF in nephrotic syndrome 1251
11. Hirschberg R: Bioactivity of glomerular ultrafiltrate during heavy 14. Wrana J: TGF-beta receptors and signaling mechanisms. Miner
Electrolyte Metab 24:120–130, 1998proteinuria may contribute to renal tubulo-interstitial lesions: Evi-
15. Ando T, Okuda S, Yanagida T, Fujishima M: Localization ofdence for a role for insulin-like growth factor I. J Clin Invest
TGF-beta and its receptors in the kidney. Miner Electrolyte Metab98:116–124, 1996
24:149–153, 199812. Hirschberg R, Ding H, Wanner C: Effects of insulin-like growth
16. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkinfactor I on phosphate transport in cultured proximal tubule cells.
DB: Latent transforming growth factor-beta: Structural featuresJ Lab Clin Med 126:428–434, 1995 and mechanisms of activation. Kidney Int 51:1376–1382, 1997
13. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, 17. Hocevar B, Howe P: Mechanisms of TGF-beta induced cell cycle
Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio arrest. Miner Electrolyte Metab 24:131–135, 1998
PM: Extracellular proteolytic cleavage by urokinase is required 18. Eddy AA: Experimental insights into the tubulointerstitial disease
for activation of hepatocyte growth factor/scatter factor. EMBO accompanying primary glomerular lesions. (editorial) J Am Soc
Nephrol 5:1273–1287, 1994J 11:4825–4833, 1992
